Mounjaro before and after 6 months: what changes, what doesn't, and what the trials actually found

You've been on Mounjaro for six months, here's what the data says about where you likely are

Picture the scenario: it's around the six-month point, your pen arrives as usual, and you step on the scales wondering how your result compares to what was promised. The SURMOUNT-1 trial, which followed 2,539 adults with obesity over 72 weeks and was published in the New England Journal of Medicine, gives the clearest benchmark. At the 15mg dose, participants had achieved roughly 16–18% average body-weight reduction by the six-month mark, with the full 72-week average reaching around 20–21%. At 10mg the trajectory was somewhat lower; at 5mg, lower still. So if you're at six months and not yet at your highest tolerated dose, your trajectory may still have some distance to run.

Weight loss across the trial was not a smooth curve. The steepest drop tended to come in the first eight to twelve weeks, after which the weekly rate slowed but continued. By six months, most trial participants were well into that steadier second phase. That's worth understanding because people sometimes interpret the slowing as stalling, it usually isn't. It's the normal shape of the response.

If you want a sense of how that earlier arc looks, our page on Mounjaro before and after three months sets out what the data shows at that mid-point. The six-month picture builds directly on it.

What's actually happening in your body at the six-month point

Tirzepatide works by activating both GIP and GLP-1 receptors, two gut hormone pathways involved in appetite signalling, blood-sugar regulation, and how quickly the stomach empties. The NHS describes this dual mechanism on its tirzepatide medicines page. By six months, that mechanism has had time to establish itself fully. Appetite suppression tends to be well set; the early nausea and digestive disruption that many people notice when starting or increasing a dose has usually settled into a background level most find manageable.

The dose ladder matters here. Treatment starts at 2.5mg, a dose designed to let the body adjust, not to drive the main therapeutic effect. From there, titration typically moves in four-weekly steps: 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg. Six months in, many people are at or near a higher maintenance dose, which is partly why the results at this milestone are more pronounced than at one or two months. If you're curious about what progress looks like at the very start, the one-month picture is a useful comparison point.

Individual variation is real. Genetics, starting weight, how closely someone has been able to follow dietary guidance alongside treatment, and whether any dose increases were delayed for tolerability reasons, all of these shape where any individual lands at six months. Clinical trials report averages across large groups; your result sits somewhere in that distribution, not necessarily at its centre.

What changes beyond the scales, and what six months doesn't fix

The SURMOUNT-1 participants who reached the highest doses didn't just lose weight. The trial also captured improvements in waist circumference, blood pressure, and markers related to blood-sugar regulation. These are the kinds of changes that matter clinically, which is part of why NICE recommended tirzepatide in December 2024, its appraisal (TA1026) is the relevant UK guidance and is publicly available on the NICE website.

What six months doesn't reliably do is lock in the result permanently. The trial data is clear that weight tends to return when treatment stops, because the underlying biology that tirzepatide addresses is still present. That's not a failure of the medicine; it's the nature of weight as a chronic condition shaped by biology rather than willpower. Our page on how long people stay on Mounjaro covers this question in more detail. It comes up a lot, and it deserves a straight answer.

Side effects at six months are worth a brief note. Most people who experience significant nausea do so early, at the start of treatment or after a dose increase. By the six-month mark that pattern has usually settled. Serious side effects including symptoms that could indicate pancreatitis (severe stomach pain reaching through to the back) should always be reported to a clinician promptly, and any suspected side effects from a licensed medicine can be submitted via the MHRA's Yellow Card scheme. Knowing that reporting route exists is worth keeping in mind throughout treatment.

How the six-month result compares, and what comes next

People sometimes arrive at the six-month point having heard about results on other GLP-1 medicines and wonder how Mounjaro's performance stacks up. In the SURMOUNT-5 head-to-head trial (published in the New England Journal of Medicine in 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and without diabetes. That's a useful reference point, though clinical context always matters more than a headline number, body weight, comorbidities, dose tolerability and treatment history all affect what's right for any individual.

For anyone comparing their own progress against trial averages at this point, our overview of weekly weight loss on Mounjaro puts the numbers in a more granular frame, and the broader Mounjaro treatment overview covers the medicine's full UK-licensed profile. For context on how the private market is priced if you're weighing up your options, the Mounjaro price comparison page sets that out plainly. The thing to weigh alongside cost is what's included, clinical oversight, prescriber reviews before every repeat, and responsive aftercare are what make the difference over a treatment period that runs months rather than days.

If you're at the six-month mark and wondering whether your result is on track, or you haven't started yet and want to understand what's realistic, the clearest next step is a clinical conversation. At nume, your free consultation is reviewed the same day by a real prescriber (a named clinician reads your answers, not a piece of software) so you get a considered response, not an automated tick-box.